Supriya Lifescience Ltd., a global pharmaceutical leader, has made significant strides in expanding its international footprint:
- Approval for Esketamine Hydrochloride in Brazil:
Supriya became the first Indian company to receive approval from Brazil’s health authority, ANVISA, for Esketamine Hydrochloride. This vital drug treats mental illness and positions Supriya to address the growing demand for cost-effective, high-quality healthcare in the LATAM region. - Atorvastatin Patent Filing:
Supriya has developed a groundbreaking, low-cost method for manufacturing atorvastatin, a globally critical drug used for managing cholesterol and cardiovascular health. The innovation focuses on affordability and efficacy, demonstrating Supriya’s commitment to accessible healthcare.
Dr. Satish Wagh, Executive Chairman, stated –
Our commitment to transforming pharmaceutical manufacturing while maintaining affordability is demonstrated by our invention in the synthesis of atorvastatin. Our global presence is strengthened by the CADIFA approval, which also allows us to introduce cutting-edge therapies like Esketamine Hydrochloride in important foreign countries, starting with Brazil.
These developments underscore Supriya Lifescience’s dedication to transforming pharmaceutical manufacturing and addressing critical healthcare needs in emerging markets.
